Literature DB >> 19934296

Do we need a different set of response assessment criteria for tumor immunotherapy?

Antoni Ribas1, Bartosz Chmielowski, John A Glaspy.   

Abstract

Tumor shrinkage induced by tumor immunotherapy may be preceded by inflammatory changes. This confounds the assessment of response rates to tumor immunotherapy. In this issue of Clinical Cancer Research, Wolchok et al. attempt to address this peculiarity by proposing a new set of criteria termed immune-related response criteria.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19934296     DOI： 10.1158/1078-0432.CCR-09-2376

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


  42 in total

Review 1.  Therapeutic cancer vaccines: are we there yet?

Authors:  Christopher A Klebanoff; Nicolas Acquavella; Zhiya Yu; Nicholas P Restifo
Journal:  Immunol Rev       Date:  2011-01       Impact factor: 12.988

2.  Humoral Immune Response against Nontargeted Tumor Antigens after Treatment with Sipuleucel-T and Its Association with Improved Clinical Outcome.

Authors:  Debraj GuhaThakurta; Nadeem A Sheikh; Li-Qun Fan; Harini Kandadi; T Craig Meagher; Simon J Hall; Philip W Kantoff; Celestia S Higano; Eric J Small; Thomas A Gardner; Kate Bailey; Tuyen Vu; Todd DeVries; James B Whitmore; Mark W Frohlich; James B Trager; Charles G Drake
Journal:  Clin Cancer Res       Date:  2015-02-03       Impact factor: 12.531

3.  Neoadjuvant PD-1 Blockade in Resectable Lung Cancer.

Authors:  Patrick M Forde; Jamie E Chaft; Kellie N Smith; Valsamo Anagnostou; Tricia R Cottrell; Matthew D Hellmann; Marianna Zahurak; Stephen C Yang; David R Jones; Stephen Broderick; Richard J Battafarano; Moises J Velez; Natasha Rekhtman; Zachary Olah; Jarushka Naidoo; Kristen A Marrone; Franco Verde; Haidan Guo; Jiajia Zhang; Justina X Caushi; Hok Yee Chan; John-William Sidhom; Robert B Scharpf; James White; Edward Gabrielson; Hao Wang; Gary L Rosner; Valerie Rusch; Jedd D Wolchok; Taha Merghoub; Janis M Taube; Victor E Velculescu; Suzanne L Topalian; Julie R Brahmer; Drew M Pardoll
Journal:  N Engl J Med       Date:  2018-04-16       Impact factor: 91.245

4.  A Primer on RECIST 1.1 for Oncologic Imaging in Clinical Drug Trials.

Authors:  Kathleen Ruchalski; Marta Braschi-Amirfarzan; Michael Douek; Victor Sai; Antonio Gutierrez; Rohit Dewan; Jonathan Goldin
Journal:  Radiol Imaging Cancer       Date:  2021-05

Review 5.  Releasing the brake on the immune system: ipilimumab in melanoma and other tumors.

Authors:  Ahmad Tarhini; Ernest Lo; David R Minor
Journal:  Cancer Biother Radiopharm       Date:  2010-12       Impact factor: 3.099

6.  Long-lasting complete response of metastatic melanoma to ipilimumab with analysis of the resident immune cells.

Authors:  Birgit Tsaknakis; Inga-Marie Schaefer; Harald Schwörer; Carsten-Oliver Sahlmann; Kai-Martin Thoms; Martina Blaschke; Giuliano Ramadori; Silke Cameron
Journal:  Med Oncol       Date:  2013-12-14       Impact factor: 3.064

7.  Melanoma: a model for testing new agents in combination therapies.

Authors:  Paolo A Ascierto; Howard Z Streicher; Mario Sznol
Journal:  J Transl Med       Date:  2010-04-20       Impact factor: 5.531

8.  Multicenter phase II study of matured dendritic cells pulsed with melanoma cell line lysates in patients with advanced melanoma.

Authors:  Antoni Ribas; Luis H Camacho; Sun Min Lee; Evan M Hersh; Charles K Brown; Jon M Richards; Maria Jovie Rodriguez; Victor G Prieto; John A Glaspy; Denise K Oseguera; Jackie Hernandez; Arturo Villanueva; Bartosz Chmielowski; Peggie Mitsky; Nadège Bercovici; Ernesto Wasserman; Didier Landais; Merrick I Ross
Journal:  J Transl Med       Date:  2010-09-27       Impact factor: 5.531

Review 9.  Nivolumab in melanoma: latest evidence and clinical potential.

Authors:  Douglas B Johnson; Chengwei Peng; Jeffrey A Sosman
Journal:  Ther Adv Med Oncol       Date:  2015-03       Impact factor: 8.168

10.  Long term survival with cytotoxic T lymphocyte-associated antigen 4 blockade using tremelimumab.

Authors:  Zeynep Eroglu; Dae Won Kim; Xiaoyan Wang; Luis H Camacho; Bartosz Chmielowski; Elizabeth Seja; Arturo Villanueva; Kathleen Ruchalski; John A Glaspy; Kevin B Kim; Wen-Jen Hwu; Antoni Ribas
Journal:  Eur J Cancer       Date:  2015-09-10       Impact factor: 9.162
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.